eFoodSafety.com, Inc. Completes Successful Double Blind Phase I Clinical Study

Newsletter

January 18, 2007

Volume VIII, Issue 6

Home Page : www.otcjournal.com
Email Questions or Comments To: editor@otcjournal.com

To OTC Journal Members:

Comments in the BLOG

I have some 411 on why PNWIF is climbing the charts so rapidly- to be disclosed in the weekend edition. The stock is closing in rapidly on my short term target price of $4 (122% return from September 23rd when I introduced the company), but there are those who believe this stock could be worth a hell of a lot more. In the last BLOG on PNWIF I mistakenly showed the Canadian symbol as PNI- I forgot about the symbol change. The correct symbol is PN on the TSX. There are new BLOGS reviewing the behavior of TTGL post earnings report and THE HAWK (NIHK, of course).

The BLOG is your opportunity to ask questions and offer comments. I will make an effort to answer every legitimate question. If I don't know the answer, I will contact the management and get the answer. Alternatively, if you have questions you don't want publicly displayed, you can always email me directly at editor@otcjournal.com.

To use the BLOG, simply go to the home page at www.otcjournal.com - the BLOG scrolls down from the upper right hand corner. The most current journal entries appear on the right hand side of you screen. Check back frequently for updates particularly when stocks are moving to overbought or oversold levels in volatile markets.

eFoodSafety (OTC BB: EFSF): Cinnergen Sales Already Rolling

Investors haven't grasped the importance of this past Tuesday's AM press release on the clinical study conducted concerning the effectiveness of Cinnergen.

This study, which proves Cinnergen is an effective product for managing blood glucose levels in both diabetics and non diabetics, will help vault sales to new levels, and the market doesn't quite get the importance- yet.

Investors may start to get the message this AM as the company announced Cardinal Health (NYSE: CAH), sporting a mere $81 billion in annual sales, has picked up Cinnergen for distribution to its 33,000 strong pharmacy network.

So, you might think I am going to show you today's news on the Cardinal Health shipment. You would be wrong. I don't think it is as important as Tuesday morning's release on the clinical trial. Why? Because the company can now legally claim this product naturally helps regulate blood sugar. Not only does this product now help diabetics, the clinical trial demonstrates Cinnergen has the potential to help with weight loss.

So, why is the study so important? Because, in my view, it will bring in a plethora of new retailers who will carry the product, and this should help take the stock to higher levels.

Diabetes and obesity have reached epidemic proportions in the US today thanks in large part to fast and processed foods. These foods are loaded with bad carbs, which have high levels of simple sugars. Simple sugar turns to fat unless your body metabolizes it and uses it for fuel. Cinnergen helps your body metabolize sugar more effectively. Ergo- if you are on an eating plan that cuts back on the bad carbs, your body will metabolize those you consume much better and aid in weight loss.

Americans will spend any amount of money for a simple, painless solution to excess fat. Swallowing one cap full in the morning of a not unpleasant tasting liquid for $30 per month seems pretty easy to me.

I looked at a short term chart, and could not find anything to indicate the stock was imminently oversold. After all, it has only pulled back 1 penny from the post coverage high.

However, this longer term picture gives you an idea of the upside in this idea. There was a major trend change last week when the stock erupted from its oversold condition, and regardless of the upcoming ups and downs, compared to where this stock has been, there is a lot of room to run.

I took the liberty of ignoring the big spike to $.60 last March as an aberration- that could have been just a few trades on that massive spike. The downtrend really started after the pullback and rebound.

There is one other very important reason for me to believe this stock has a lot of upside. The company has no plans to enter into any financing arrangements- no massive supplies of cheap stock will be hitting the market. That part of the process is already over with.

The Cardinal Health purchase announced this AM will probably be the first in a series of new buyers to come to the table for this product. The reason they are coming- the results of the clinical trial. It's the most important event you can read about right now.

Here is the complete text of Tuesday's news release concerning the clinical trial for your review:

Press Release Source: eFoodSafety.com, Inc.

eFoodSafety.com, Inc. Completes Successful Double Blind Phase I Clinical Study Meeting FDA Guidelines Demonstrating the Positive Effect of Cinnergen(TM) in the Management of Diabetes

Tuesday January 16, 9:50 am ET

Results from 50-Patient Controlled Study Conducted by Bucks County Clinical Research Center Surpass Expectations

SCOTTSDALE, Ariz.--(BUSINESS WIRE)--eFoodSafety.com, Inc. (OTCBB:EFSF - News), a Company dedicated to improving health conditions around the world through innovative products and technologies, today announced that it has completed a Double Blind Phase I Study on Cinnergen(TM), an all natural liquid nutritional supplement designed to regulate blood sugar. The clinical study was conducted by Bucks County Clinical Research Center, which has been doing research for over 20 years for major pharmaceutical companies worldwide. Bucks County Clinical Research Center (www.bccrinc.com) is a fully licensed FDA research center.

The study followed 50 patients with Type I and Type II diabetes over a 90-day period and reported results from a Quality of Life survey completed by each patient. The results from the study showed that 52% of the patients taking 1 ounce of Cinnergen(TM) each day exhibited well controlled blood sugars by using Cinnergen(TM) alone. The remaining 48% of the patients who used 1 ounce of Cinnergen(TM) with their previously prescribed diabetic medications were able to decrease the amount of their medications in order to effectively control their diabetes.

The study also measured the Hemoglobin A1C levels at the beginning and at the conclusion of the study. The diabetic patients on only Cinnergen(TM) had an impressive 70% improvement in this important medical monitoring tool which gives an accurate estimate of long-term blood sugar control.

An impressive 75% of study subjects reported positive changes in their Quality of Life, such as convenience of use, pleasant taste, and increase in energy level, as well as improvement in sleep habits, mental alertness, mood, libido, dietary habits, and an overall feeling of well being. They also reported a marked decrease in illness.

The conclusion by Bucks County Clinical Research Center is that all patients, pre-diabetic or diabetic, would benefit from the use of Cinnergen(TM) on a daily basis.

Patricia Gruden, President and CEO of eFoodSafety.com, Inc., stated, "With these positive, clinically demonstrated results, which exceeded expectations, we will be able to provide major retailers the opportunity to present Cinnergen(TM) to their customers with confidence. We expect Cinnergen(TM) sales to grow significantly as we market our proven claims to our advertisers and retailers, assuring them that they are providing a well studied and quality product that will impact and improve the health and well being of their consumers."

About eFoodSafety.com, Inc.

eFoodSafety.com, Inc. is dedicated to improving health conditions around the world through its innovative technologies. The company's Knock-Out Technologies, Ltd. subsidiary has developed an environmentally safe sporicidal product formulated entirely of food-grade components that eradicates anthrax and a germicidal product, Citroxin (formerly named Big Six Plus) - EPA Reg. No. 82723-1 - that kills six major bacteria: E-coli, Listeria, Pseudomonas, Salmonella, Staphylococcus, and Streptococcus, Avian Influenza, and Black Mold. The sporicidal product has completed its final efficacy laboratory study requisite for EPA registration. In the study, it eradicated both Clostridium Sporogenes and Bacillus Subtilis with 100% efficacy on both hard and porous surfaces. The company's MedElite, Inc. subsidiary distributes clinically proven products to physicians who then prescribe the products for their patients. It recently became the owner of the Talsyn(TM)-CI/bid Scar Cream, which has been clinically proven to facilitate and improve the appearance, redness, and strength of scars (www.talsyn.com), as well as seven (7) other products in the Talsyn(TM) line. The company is also owner of Cinnergen(TM), a clinically studied, non-prescription liquid whole food nutritional supplement that promotes healthy glucose metabolism (www.cinnergen.com). The company has entered into a joint venture agreement with CK41 Direct, Inc. to launch the PurEffect(TM) anti-acne skin care system.

Please visit the Company's website at: http://www.efoodsafety.com.

Safe Harbor Forward-Looking Statements

Statements contained in this release that are not strictly historical are "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements are made based on information available as of the date hereof, and the Company assumes no obligation to update such forward-looking statements. Editors and investors are cautioned that such forward-looking statements involve risks and uncertainties and the company's actual results may differ from these forward-looking statements. Such risks and uncertainties include but are not limited to demand for the Company's products and services, our ability to continue to develop markets, general economic conditions, our ability to secure additional financing for the Company, and other factors that may be more fully described in reports to shareholders and periodic filings with the Securities and Exchange Commission.

Contact:

Redwood Consultants, LLC
Jens Dalsgaard, 415-884-0348

Source: eFoodSafety.com, Inc.

Subscribe

Information is power and timely information is profitable. Become informed and profit from OTC Journal Profiles and Trading Alerts by becoming a Preferred Member today. There is no cost associated with your email subscription. Add your email address below and make sure to check your email inbox and confirm your opt-in request to start receiving the OTC Journal Email Newsletter on a regular basis.

To ensure newsletter delivery, you can add any additional email addresses you may have to the OTC Journal Member List. Receiving the OTC Journal Newsletter in multiple locations is the best way of making sure you don't miss the next investing or trading opportunity! For web based email addresses, the OTC Journal recommends @yahoo.com or @aol.com for timely and reliable email newsletter delivery.

Note: Your email address will be kept strictly confidential, and will not be shared with any other entity for any purpose at any time. If you no longer wish to receive the OTC Journal, simply follow the instructions located at the bottom of every OTC Journal Newsletter Edition.

Disclaimer

The OTCjournal.com Newsletter is an independent electronic publication committed to providing our readers with factual information on selected publicly traded companies. All companies are chosen on the basis of certain financial analysis and other pertinent criteria with a view toward maximizing the upside potential for investors while minimizing the downside risk, whenever possible. Moreover, as detailed below, this publication accepts compensation from certain of the companies which it features. Likewise, this newsletter is owned by MarketByte, LLC. To the degrees enumerated herein, this newsletter should not be regarded as an independent publication.

Go Here to view our compensation on every company we have ever covered, or visit the following web address: http://www.otcjournal.com/disclaimer.html for our full profiles and http://www.otcjournal.com/trading-alerts/disclaimer.html for Trading Alerts. MarketByte LLC has been paid a fee of $30,000 cash and 1 million newly issued restricted shares by eFoodSafety for coverage of the company.

All statements and expressions are the sole opinions of the editors and are subject to change without notice. A profile, description, or other mention of a company in the newsletter is neither an offer nor solicitation to buy or sell any securities mentioned. While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein.

From time to time MarketByte LLC sells shares in the open market it receives as compensation for coverage of client companies. Since the shares are received as compensation for services as previously disclosed, and not for investment purposes, the editors do not view the sale of the shares as contradictory to any advice delivered in the content. This should be viewed as a conflict of interest by shareholders or prospective shareholders of the client companies.

The editor, members of the editor's family, and/or entities with which they are affiliated aside from MarketBtye LLC itself, are forbidden by company policy to own, buy, sell or otherwise trade stock for their own benefit in the companies who appear in the publication unless specifically disclosed in the newsletter. Some of the companies featured in the OTC Journal pay a cash ESP fee to an affiliated technology company ranging from $2,000 to $5,000 per month for internet related technology services.

The Trustee of the MarketByte LLC Defined Benefit and Trust (“the MarketByte Pension Plan”) has invested approximately The Trustee of the MarketByte LLC Defined Benefit and Trust (“the MarketByte Pension Plan”) has invested approximately $310,0000 in the Longview Fund (“the Longview Limited Partnership”), a limited partnership in which the MarketByte Pension Plan is a limited partner. No one associated with the MarketByte Pension Plan has any knowledge, information, or control as to any past, present, or future investment activities of the Longview Fund. Longview ocassoinally refers companies to MarketByte LLC for possible coverage by one of the MarketByte LLC publications, which publications include The OTCJournal.com Newsletter. Longview may or may not own shares in the companies that it so refers to MarketByte. MarketByte has no information (outside of information readily accessible to the general public such as SEC filings) as to whether Longview owns any shares in the companies that it refers to MarketByte LLC. The above relationships should be viewed as a potential and/or actual conflict of interest by shareholders and prospective shareholders of MarketByte LLC client companies.

The profiles, critiques, and other editorial content of the OTCjournal.com may contain statements that appear foward relating to the expected capabilities of the companies mentioned herein.

THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. THE INFORMATION FOUND IN THIS PROFILE IS PROTECTED BY THE COPYRIGHT LAWS OF THE UNITED STATES AND MAY NOT BE COPIED, OR REPRODUCED IN ANY WAY WITHOUT THE EXPRESSED, WRITTEN CONSENT OF THE EDITORS OF OTCjournal.com.

We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission ("SEC") at http://www.sec.govand/or the National Association of Securities Dealers ("NASD") at http://www.nasd.com. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at http://www.sec.gov/consumer/cyberfr.htm. Disclaimer ID:$subst('Recip.userid') Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site. MarketByte LLC's mailing address is 4653 Carmel Mtn Rd Suite 308 #402, San Diego, CA 92130.

You can unsubscribe from this list at any time by Clicking Here and HITTING SEND. If you are having difficulty removing yourself or wish to change your address please go to http://listserv.otcjournal.com/opt.cgi?.